As Regeneron Worries Rise On Eylea Combo Failure, Eyes Turn To PANORAMA

Failure of RUBY and ONYX combo trials with Eylea and nesvacumab fan concerns over longer-term growth prospects for Regeneron's ophthalmic franchise.